Brad Campbell named Travere CEO, succeeding Eric Dube effective Dec 1

Travere Therapeutics, Inc.

Eric Dube steps down as Travere President/CEO and Director effective Dec 1, 2026, remaining Executive Advisor until Feb 15, 2027.
Bradley Campbell (ex-CEO of Amicus until its Apr 2026 BioMarin acquisition) starts as President/CEO and Director on Dec 1, 2026.
Campbell receives $1.0M base salary, 85% target bonus, $500k expense payment, and ~$16.5M initial equity (option + RSUs); ~$3.75M performance RSU in 2027.
Dube keeps salary through Feb 2027, eligible for 75% 2026 bonus, but no 2027 bonus or new equity; performance RSUs cease vesting at separation.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Bradley L. Campbell

President and Chief Executive Officer

TVTX · Travere Therapeutics, Inc.

Effective: 2026-12-01
Filed: September 21, 2026, 4:10 PM ET

Bradley L. Campbell has been named as Dr. Dube’s successor with his appointment as President and Chief Executive Officer and as a member of the Board of Directors to be effective as of the Officer Resignation Date.

Appointed

Eric Dube

Executive Advisor

TVTX · Travere Therapeutics, Inc.

Effective: 2026-12-01
Filed: September 21, 2026, 4:10 PM ET

As discussed in greater detail below, Dr. Dube has agreed to continue with the Company as Executive Advisor through February 15, 2027, to facilitate a smooth transition of responsibilities and has agreed to serve as Consultant to the Chief Executive Officer for a period following the employment transition.

Appointed

Bradley L. Campbell

Member of the Board of Directors

TVTX · Travere Therapeutics, Inc.

Effective: 2026-12-01
Filed: September 21, 2026, 4:10 PM ET

Bradley L. Campbell has been named as Dr. Dube’s successor with his appointment as President and Chief Executive Officer and as a member of the Board of Directors to be effective as of the Officer Resignation Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bradley L. Campbell was appointed as President and Chief Executive Officer at Travere Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

Bradley L. Campbell has been named as Dr. Dube’s successor with his appointment as President and Chief Executive Officer and as a member of the Board of Directors to be effective as of the Officer Resignation Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.8

Eric Dube was appointed as Executive Advisor at Travere Therapeutics, Inc..

Action: agreed to continue as
Role: Executive Advisor

Exact text from the filing

As discussed in greater detail below, Dr. Dube has agreed to continue with the Company as Executive Advisor through February 15, 2027, to facilitate a smooth transition of responsibilities and has agreed to serve as Consultant to the Chief Executive Officer for a period following the employment transition.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Bradley L. Campbell was appointed as Member of the Board of Directors at Travere Therapeutics, Inc..

Action: appointed
Role: Member of the Board of Directors

Exact text from the filing

Bradley L. Campbell has been named as Dr. Dube’s successor with his appointment as President and Chief Executive Officer and as a member of the Board of Directors to be effective as of the Officer Resignation Date.

View on SEC.gov

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001438533-26-000068

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.